Notable Runner: What’s in vTv Therapeutics Inc After Touching 52-Week Low?

Notable Runner: What's in vTv Therapeutics Inc After Touching 52 Week Low?

The stock of vTv Therapeutics Inc (NASDAQ:VTVT) hit a new 52-week low and has $4.21 target or 14.00% below today’s $4.90 share price. The 9 months bearish chart indicates high risk for the $150.30M company. The 1-year low was reported on Nov, 7 by If the $4.21 price target is reached, the company will be worth $21.04M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 29,530 shares traded hands or 20.25% up from the average. vTv Therapeutics Inc (NASDAQ:VTVT) has declined 3.79% since April 5, 2016 and is downtrending. It has underperformed by 5.75% the S&P500.

Analysts await vTv Therapeutics Inc (NASDAQ:VTVT) to report earnings on November, 10. They expect $-0.55 earnings per share, down 12.24% or $0.06 from last year’s $-0.49 per share. After $-0.47 actual earnings per share reported by vTv Therapeutics Inc for the previous quarter, Wall Street now forecasts 17.02% negative EPS growth.

vTv Therapeutics Inc (NASDAQ:VTVT) Ratings Coverage

Out of 3 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. vTv Therapeutics Inc has been the topic of 3 analyst reports since August 24, 2015 according to StockzIntelligence Inc. As per Monday, August 24, the company rating was initiated by Stifel Nicolaus. Piper Jaffray initiated the stock with “Overweight” rating in Monday, August 24 report. Canaccord Genuity initiated it with “Buy” rating and $15 target price in Friday, September 4 report.

According to Zacks Investment Research, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.”

More notable recent vTv Therapeutics Inc (NASDAQ:VTVT) news were published by: which released: “vTv Therapeutics Reports Third Quarter Financial and Operational Results and …” on November 02, 2016, also with their article: “vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer” published on December 02, 2015, published: “BRIEF-vTv Therapeutics reports Q3 financial and operational results and re…” on November 02, 2016. More interesting news about vTv Therapeutics Inc (NASDAQ:VTVT) were released by: and their article: “vTv Therapeutics Inc. Announces Pricing of Initial Public Offering” published on July 20, 2015 as well as‘s news article titled: “vTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 for the Treatment …” with publication date: January 21, 2016.

VTVT Company Profile

vTv Therapeutics Inc., incorporated on April 02, 2015, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery and development of orally administered small molecule drug candidates. The Company’s drug candidate for the treatment of Alzheimer’s disease (AD), azeliragon (TTP488), is an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial (the STEADFAST Study) under a Food and Drug Administration (FDA) agreed Special Protocol Assessment (SPA). The Company’s type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial (the AGATA Study), and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment